GEA Supports Angola’s Vaccine Production with Biopharmaceutical Separation Solutions

The new Veterinary Vaccine Institute in Huambo, Angola, is equipped with state-of-the-art separation technology. A CSC 6 stainless steel disc centrifuge and a CIP (“Clean in Place”) system are being installed. (Photo: GEA)

(IN BRIEF) GEA is equipping the new Veterinary Vaccine Institute in Huambo, Angola, with advanced separation and aseptic valve technology, including a CSC 6 disc centrifuge, a CIP system and GEA VESTA® sterile valves. Scheduled for commissioning in autumn 2026, the facility will produce a wide range of animal vaccines, reducing reliance on imports and supporting agricultural development across Africa. The project, delivered on behalf of the Angolan government, combines biopharmaceutical-grade technology with high hygiene and process safety standards to support sustainable vaccine production and local innovation.

(PRESS RELEASE) DÜSSELDORF, 15-Jan-2026 — /EuropaWire/ — GEA is supplying advanced separation and aseptic valve technology for the new Veterinary Vaccine Institute under construction in Huambo, Angola, supporting the country’s ambition to strengthen domestic vaccine production and agricultural resilience. The project includes the installation of a CSC 6 stainless steel disc centrifuge and a fully automated CIP (Clean-in-Place) system, both equipped with GEA VESTA® sterile valves to ensure high levels of process safety and hygiene.

GEA developed the CSC 6 centrifuge for the pharmaceutical biotechnology industry in accordance with the currently applicable cGMP requirements (“Current Good Manufacturing Practice”). (Photo: GEA)

The bioveterinary centre is being delivered by GAUFF Engineering in cooperation with NORÁFRICA on behalf of the Angolan government, represented by the Ministry of Agriculture and Forestry (MINAGRIF), with GEA acting as a key technology supplier. The strategic importance of the project was underscored by the visit of German President Frank-Walter Steinmeier to the construction site in early November 2025, highlighting the international significance of the initiative and the collaboration involved.

Once commissioned in autumn 2026, the Veterinary Vaccine Institute will produce a broad portfolio of animal vaccines for cattle, pigs, goats, sheep and poultry. The facility is intended to reduce Africa’s reliance on imported veterinary vaccines while supporting more efficient and profitable livestock farming. In addition to production capabilities, the centre will house research and development laboratories as well as quality testing and control facilities, enabling innovation tailored to African pathogens and local conditions.

GEA VESTA® sterile valves are part of GEA’s aseptic valve technology and feature a completely hermetic sealing system. (Photo: GEA)

The CSC 6 disc centrifuge supplied by GEA has been specifically developed for biopharmaceutical and biotechnology applications and meets current cGMP (Current Good Manufacturing Practice) requirements. Designed for aseptic processing, the system is steam-sterilisable (SIP up to 2.5 bar at 137°C) and features a fully automated CIP process, supported by the dedicated cleaning system supplied as part of the project.

For sensitive biopharmaceutical products, the CSC 6 incorporates GEA’s patented hydrohermetic feed system, which ensures gentle handling and optimal clarification. The integrated GEA Hydrostop system enables the discharge of concentrated solids at operating speed with high dry matter content, allowing uninterrupted operation. All product-contact components are manufactured from high-alloy stainless steel with a surface finish of 0.8 µm or better, while seals comply with FDA and USP Class VI standards.

Process and product safety are further enhanced through the use of GEA VESTA® sterile valves, which form part of GEA’s aseptic valve technology portfolio. The valves feature a fully hermetic sealing system based on a one-piece PTFE bellows, reliably separating the product area from the environment. Designed for hygienically demanding applications in pharmaceuticals and biotechnology, the valves support CIP and SIP processes, offer high chemical resistance and allow for efficient maintenance through easily accessible components and reusable bellows units.

Through its contribution to the Huambo Veterinary Vaccine Institute, GEA is supporting Angola’s efforts to diversify its economy, strengthen food security and build sustainable healthcare and agricultural infrastructure, in line with its broader commitment to engineering solutions that enhance efficiency, safety and sustainability worldwide.

Media Contact:

Dr. Michael Golek
Phone: +49 211 9136 1505

SOURCE: GEA